Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Dual Inhibition
100%
C-X-C Chemokine Receptor Type 4 (CXCR4)
100%
Acute Myeloid Leukemia
100%
AMD3100
100%
FLT3-ITD
100%
Granulocyte Colony-stimulating Factor (G-CSF)
88%
Sorafenib
66%
Stromal Cell-derived factor-1 (SDF-1)
44%
FLT3 mutation
44%
Leukemia Patients
33%
Leukemia Cells
22%
Anti-leukemia
22%
FMS-like Tyrosine Kinase 3 (FLT3)
22%
Genotype
22%
FLT3 Inhibitor
22%
Leukemic Stem Cells
22%
Prognosis4
11%
CXCR4 Axis
11%
Mutant FLT3
11%
Escalating Dose
11%
Relapsed Acute Myeloid Leukemia
11%
Cell Signaling
11%
Clinical Trials
11%
Egress
11%
Pro-apoptotic Effect
11%
Cell Inhibition
11%
Preparative Regimen
11%
Targeted Therapy
11%
Phase I Study
11%
Acute Myeloid Leukemia Cells
11%
Leukemic Cells
11%
FDA-approved Drugs
11%
Interaction Games
11%
Comprehensive Evaluation
11%
No Toxicity
11%
Biological Effects
11%
Microenvironment
11%
Leukemia
11%
Hematopoietic Cells
11%
CXCR4 Inhibitor
11%
Agent Behavior
11%
Chemoresistance
11%
Remission
11%
Hematopoietic Stem Cells
11%
Cell number
11%
Cell Mobilization
11%
Single-cell PCR
11%
Active Disease
11%
Complete Remission
11%
Therapeutic Concepts
11%
Immunology and Microbiology
Myeloid
100%
CXCR4
100%
Plerixafor
100%
Granulocyte Colony-Stimulating Factor
88%
Sorafenib
66%
Leukemia Cell
33%
Stem Cell
22%
Hematopoietic Cell
11%
Drug Resistance
11%
Sensitization
11%
Wild Type
11%
Signal Transduction
11%
Stromal Cell-Derived Factor 1
11%
Biological Activity
11%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
CXCR4
100%
Granulocyte Colony-Stimulating Factor
88%
Sorafenib
66%
Stem Cell
22%
Biological Activity
11%
Wild Type
11%
Stromal Cell-Derived Factor 1
11%
Hematopoietic Cell
11%
Clinical Trial
11%
Targeted Therapy
11%
Drug Resistance
11%
Sensitization
11%
Signal Transduction
11%